Insellar develops a patent-protected system intended to enable targeted modulation of brain activity via a brain-computer interface. The startup is pursuing applications in treatment-resistant depression and evaluating use in additional neuropsychiatric indications. Current work is concentrated on preclinical proof-of-concept studies and technical validation toward a first functional prototype. The recent €400,000 pre-seed financing from IBB Ventures and business angels will fund development and prototype construction. The company positions itself within neurotechnology and medical innovation and operates out of Berlin.

Total raised

$0M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026